Dietary triggers such as gluten and highly fermentable oligo-, di-and monosaccharides and polyols (FODMAP)-containing foods have been associated with worsening irritable bowel syndrome (IBS) symptoms. However, the true impact of dietary restriction on IBS symptoms has remained unclear. The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) examining the efficacy of exclusion diets (we focused on low FODMAP and gluten-free diets (GFD)) in IBS.
MethOds:
We conducted a search of the literature using the electronic databases MEDLINE (1946 to November 2017), EMBASE (1974 to November 2017), Cochrane Central Register of Controlled Trials (November 2017), and Cochrane Database of Systematic Reviews (2005 to November, 2017) for RCTs of exclusion diets in IBS. Two independent reviewers screened citations and a third reviewer resolved disagreement. Two independent reviewers performed eligibility assessment and data abstraction. For inclusion, RCTs that evaluated an exclusion diet versus an alternative or usual diet and assessed improvement in either global IBS symptoms or abdominal pain were required. Data were synthesized as relative risk of symptoms remaining using a random effects model. Quality of evidence was assessed using GRADE methodology.
Results:
A total of 1726 citations were identified. After full-text screening a total of nine studies were eligible for the systematic review. There were two RCTs of a GFD, involving 111 participants. Both selected patients who responded to a GFD and then randomized them to continue the diet or have the diet "spiked" with gluten. A GFD was associated with reduced global symptoms compared with a control diet (RR = 0.42; 95% CI 0.11 to 1.55; I 2 = 88%), although this was not statistically significant. There were seven RCTs comparing a low FODMAP diet with various control interventions in 397 participants. A low FODMAP diet was associated with reduced global symptoms compared with control interventions (RR = 0.69; 95% CI 0.54 to 0.88; I 2 = 25%). The three RCTS that compared low FODMAP diet with rigorous control diets had the least heterogeneity between studies, but also the least magnitude of effect. The overall quality of the data was "very low" according to GRADE criteria.
cOnclusiOns: There is insufficient evidence to recommend a GFD to reduce IBS symptoms. There is very low quality evidence that a low FODMAP diet is effective in reducing symptoms in IBS patients.
reduction in quality of life, as well as anxiety and depression [3] . A positive diagnosis of IBS can be made on symptom-based criteria [4] and there are a number of different therapies including manipulating the microbiome and pharmacological and psychological approaches [5] . Pharmacological therapies can be effective, but surveys suggest that about 50% of patient with IBS use other approaches either in addition to, or instead of, conventional medical therapy [6] , and over 60% report that particular foods trigger their symptoms [7, 8] . Patients with IBS are therefore often interested in exploring dietary interventions for their symptoms. It is important to give patients evidence-based advice on which diets may be effective in reducing their symptoms. Initial approaches that based dietary recommendations for food sensitivities had disappointing efficacy in randomized trials [9] , but recent dietary approaches have shown more promise. It has been hypothesized that a subset of patients with IBS may have an intolerance of gluten, despite not having celiac disease [10] . This has led some to recommend a gluten-free diet (GFD) in IBS. Another approach has been to reduce fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) in the diet. This is the most widely adopted diet in IBS and may improve IBS symptoms [11] . Systematic reviews of studies evaluating a GFD and a low FODMAP diet have provided conflicting conclusions [12, 13] , but all have suggested more data are needed. Since publication of these systematic reviews, there have been additional randomized controlled trials (RCTs) evaluating exclusion diets in IBS [14, 15] .
The aim of this study was to conduct an updated systematic review of RCTs assessing the impact of a GFD or low FODMAP diet in improving IBS symptoms in order to provide clinicians with an evidence-based assessment of the efficacy of both.
MEthodS

Search strategy and study selection
We conducted a search of the literature using the electronic databases MEDLINE (1946 to November 2017), EMBASE (1974 to November 2017), Cochrane Central Register of Controlled Trials (September 2017), and Cochrane Database of Systematic Reviews (2005 to November, 2017) via OVIDSP for RCTS of exclusion diets in IBS (See Box 1 for eligibility criteria). We included abstracts and conference proceedings from Digestive Diseases Week (2014 to 2017). There were no language restrictions. We conducted the literature search as part of the American College of Gastroenterology's updated monograph on the management of IBS (in press). Search terms included "irritable bowel syndrome", "irritable colon", "gluten free diet", "gluten free", "fructose oligosaccharide" "FODMAP or FODMAPs", "diet restriction", "fructan", "carbohydrate diet", "sweetener", etc, combined with AND terms. Additional combined terms included "clinical trials", "double blinded", "blind", or "randomized controlled trials", etc (for search strategy see Appendix 1). We contacted authors for dichotomous outcomes if these were not reported, as well as for missing data. Two independent reviewers performed screening of citations and a third reviewer resolved disagreement.
Outcome assessment
The primary outcome was global improvement in IBS symptoms. If global improvement was not reported, we used abdominal pain as the outcome of interest. If different definitions of symptom improvement were provided in the same study, we used the most stringent outcome reported that minimized placebo response rate (e.g., an improvement in IBS symptoms of >50% would be chosen ahead of an improvement in symptoms of >25%). Secondary outcomes included general quality of life and any occurrence of adverse events.
Data extraction
Two independent reviewers (JD and YY) performed data abstraction. Data extracted ( Table 1) included data on year of publication, country of origin, type of diet used, duration of therapy, primary and secondary outcomes used, IBS definition used (e.g., Rome criteria versus clinician diagnosis), the comparator intervention, and predominant stool pattern (constipation versus diarrhea) of recruited patients. Data were abstracted as an intention-to-treat analysis, with drop outs treated as treatment failures. Disagreements were resolved by a third reviewer (PM).
Assessment of risk of bias and GRADE methodology
The risk of bias assessment was performed by two independent reviewers using the Cochrane Risk of Bias Tool with ReviewManager (RevMan) (Version 5.3, Cochrane Collaboration). Each study was evaluated based upon reporting of randomization, allocation, blinding, and outcome assessment and reporting. Grading of the evidence was performed according to GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology using GRADEPro Guideline Development Tool (GDT) [16] .
Data synthesis and statistical analysis
Data analysis was performed using RevMan 5 (Version 5.3, Cochrane Collaboration). We calculated relative risk (RR) with 95% confidence intervals (CIs) of symptoms not improving in IBS compared with control. Data were pooled with a random effects model. Heterogeneity was evaluated with the I 2 statistic, with 
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rESuLtS
The literature search identified 1725 citations, and 72 studies underwent full manuscript review. After full-text screening, 63 articles were excluded, leaving a total of 9 studies eligible for the systematic review (Fig. 1) .
Gluten-free diet and IBS
There were two RCTs [17, 18] of a GFD, involving 111 participants. Both selected patients who had already responded to a GFD, and then randomized them to continue the diet, or to have the diet "spiked" with gluten. The description of the trial characteristics is given in Table 2 . One trial [17] was low risk of bias, and the other [18] was of unclear risk of bias. A greater proportion of participants had an exacerbation of their IBS symptoms among those allocated to have their diet spiked with gluten, compared with those remaining on a GFD. Both trials reported a statistically significant result, but when the two trials were pooled the results were not statistically significant (RR = 0.42; 95% CI 0.11 to 1.55; I 2 = 88%) due to the marked heterogeneity between individual trial results (Fig. 2) . Neither study reported on adverse events or general quality of life.
Low FODMAP diet and IBS
There were 7 RCTs [14, 15, [19] [20] [21] [22] [23] , comparing a low FODMAP diet with various control or control comparator interventions in 397 participants. A summary of the trial characteristics is given in Table 2 . There were no low risk of bias trials, and this was mainly due to lack of blinding. More recent studies have made excellent efforts to maintain blinding [14] but we classified studies as not blinded as the contents of a low FODMAP diet are readily available on the internet and on cell phone applications. A low FODMAP diet was associated with a reduction in global symptoms compared with controls (RR 0.69; 95% CI 0.54 to 0.88; I 2 = 25%) (Fig. 3) . One trial [14] reported general quality of life, with no difference between the two groups (mean difference = 1.30; 95% CI = −6.82 to 9.42). Two trials reported on adverse events [14, 15] but did not present data that could be extracted. Both trials reported that diets were well tolerated with no serious adverse events.
We explored reasons for heterogeneity between studies using subgroup analyses and the largest contributor to this was the 
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Low FODMAP versus an alternative diet. Three studies [14, 15, 19] of 71 patients. There were fewer patients with persistent IBS symptoms in the low FODMAP diet arm, compared with a usual diet (RR = 0.46; 95% CI 0.25 to 0.84).
Low FODMAP exclusion followed by low FODMAP challenge versus placebo. Hustoft et al. [23] implemented a low FODMAP diet and 15 patients who responded to the diet were subsequently randomized to receive a supplement, either a placebo or one containing a FODMAP. Patients receiving placebo maintained the reduction in their IBS symptoms compared with placebo, but this small study was not statistically significant (RR = 0.44; 95% CI 0.11 to 1.71).
Risk of bias and GRADE
The overall quality of the data was "very low" according to GRADE criteria (Tables 3 and 4) as most studies were unclear or high risk of bias, there was heterogeneity between study designs, and there was imprecision in the estimate of effect. 
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dIScuSSIon
The management of IBS should be evidence-based and any therapy should ideally be supported by high-quality RCTs. For many years, this had been lacking for dietary interventions in IBS, with only three eligible RCTs identified in our last systematic review on this topic [13] . There has been an increase in the quantity and quality of RCTs evaluating dietary therapies for IBS in recent years and this systematic review identified 11 RCTs, involving 508 participants, evaluating either a low FODMAP diet or a GFD. We found there was insufficient evidence to recommend a GFD, but there was very low quality evidence to support recommending a low FODMAP diet in IBS. A further RCT [24] suggested any benefit of GFD may relate to the reduction in FODMAPs consequent on this dietary change. Proponents of a low FODMAP diet for IBS may be disappointed that the quality of the evidence is not rated higher. We used GRADE methodology [25] to evaluate the quality of the evidence, which is the most widely accepted approach, and one that is used by over 100 organizations throughout the world. The reason for the very low quality rating is the different comparator groups used in individual trials, and the relatively modest numbers of patients with an improvement in global IBS symptoms. Specifically, there were only a total of 189 participants in the low FODMAP diet trials who experienced an improvement in their symptoms, whereas GRADE would ideally require 300 events for data to be classified as robust [26] . These factors could be improved with further trials using similar comparators and providing more data, although this is a challenge given there is no pharmaceutical industry support and most federal funding agencies do not rate IBS as a priority area for research funding. Indeed, researchers in this area should be congratulated on the number of participants they have recruited to RCTs to date, despite these challenges. The area that will be more difficult to address is the issue around lack of blinding. Many IBS patients are aware of the concept of a low FODMAP diet, and information on this diet is freely available. An IBS patient can, therefore, easily deduce which diet they have been allocated to if they participate in an RCT. Asking the participant which group they think they have been randomized to (so the proportion with incorrect "guesses" can be calculated) may not identify this problem as participants who have identified which group they were allocated to may not admit to this. The only robust approach would be a double-blinded challenge study, where everyone is placed on a low FODMAP diet and then randomized to continue on that diet or have their diet spiked with a high FODMAP product. Even this is challenging to interpret, as any change in diet, even if it is unrelated to IBS, can cause gastrointestinal symptoms as the gastrointestinal (GI) tract is exposed to new foods. In addition, even brief dietary interventions can change the gut microbiome, making rechallenge studies difficult to interpret. Ideally, challenge studies should, therefore, be long term in order to account for any short-term non-specific effects of foods that the GI tract has not experienced recently. Defining "long term" is a challenge in this context, but we would suggest at least 8-12 weeks of follow-up and all studies in this review were of a shorter duration.
Providers recommending the low FODMAP diet should bear in mind that exclusion of FODMAPs is only the first phase of the diet program. Exclusion for 2-6 weeks should be viewed as a diagnostic test to identify IBS patients who are sensitive to FODMAPs. Those who fail to improve should not continue the diet. Those who improve should be instructed on reintroducing foods which contain FODMAPs to determine their sensitivities. This information should then be used to liberalize and personalize the low FOD-MAP diet with the intention of improving adherence and minimizing effects on the gut microbiome.
There are much less data for a gluten-free diet or elimination diets based upon IgG antibody testing. As has already been pointed out, there are little to no data which address the long-term efficacy, adherence, or harms of diet therapies for IBS. Recommendations regarding other diets (e.g., dairy-free, lactose-free, vegetarian, etc.) cannot be made due to lack of objective information. Regardless of the gaps in the data, it is clear that diet therapies are here to stay. The complexity of diet therapies for IBS, potential for inducing nutritional deficiencies, and time and resources required to provide proper counseling provides tangible incentives to utilize a properly trained dietician. If a trained dietician is not available or a patient cannot afford to see a dietician, it is important for providers to have assembled high-quality teaching materials which can allow an IBS patient to implement diet therapy in a medically responsible manner. Overall, the sample size within each trial was small and some studies utilized a cross-over design. These two factors raise concern regarding the external validity of the results, given the high prevalence of IBS within the general population, but relatively small sample sizes recruited in the current studies. Further studies could elucidate factors that limit study enrollment. In addition, future studies should utilize a parallel RCT design rather than a cross-over RCT methodology for a common disorder. The main reason for this is that we do not know the mechanism by which exclusion diets may reduce symptoms in IBS. It could relate to the direct effect of the food, such as osmotic load to the intestine, a subtle immune response to a certain food group, or an influence on the gut microbiome that leads to GI symptoms [27] . As we do not know the mechanism, it is difficult to recommend a definitive wash-out period, and therefore cross-over trials should be avoided. RCTs could further improve our knowledge of how exclusion diets may impact on IBS by collecting mechanistic, as well as symptom, data. Indeed, some of the trials did collect microbiome and metabolomics data [14, 20] . Studies rarely reported on general quality of life or adverse events and it would be important for future trials to address this deficit. Exclusion diets may have nutritional implications for patients or adversely impact on the microbiome, so it would also be important to evaluate long-term safety concerns with a low FODMAP diet.
This study has several strengths. We used robust systematic review methodology and rigorously evaluated the quality of the evidence. The number of eligible studies has also increased significantly since this topic was last evaluated. There are, however, a number of limitations to this systematic review. As stated above, more events are needed before results can be considered robust, and there was variation in the comparator diet between trials. Freely available information on the low FODMAP diet is an issue for adequate blinding, and if new diets are developed in the future it would be advisable to keep them as confidential as possible until sufficient RCT data are collected. Finally, there was insufficient information to evaluate whether GFD or low FODMAP diet was more effective in certain subgroups of IBS patients, such as those with predominant diarrhea or bloating.
The findings of this review demonstrate that, at present, there is insufficient evidence to recommend a GFD to reduce global IBS symptoms. There is very low quality evidence that a low FODMAP diet is effective in reducing global symptoms in IBS patients. More data are needed, but of the available dietary interventions, a low FODMAP diet currently has the greatest evidence for efficacy in IBS.
